


KOREA DRUG DEVELOPMENT FUND

• YOUR GATEWAY
TO INNOVATIVE DRUG CANDIDATES
IN KOREA



WHO WE ARE

Korea Drug Development Fund (KDDF) is a national R&D initiative funded by three government ministries. We support drug development across academia and the pharmaceutical industry to advance innovative therapeutic pipelines.



Our Purpose

Driven by a mission to advance Korea's pharmaceutical innovation, KDDF will invest approximately USD 2.0 billion in 1,234 R&D projects by 2030 to accelerate the translation of innovations from academia and the pharmaceutical industry into clinically and commercially viable drug development programs.

USD 2.0Bn

To support 1,234 R&D projects between 2021 and 2030

• Exchange Rate: USD 1 = KRW 1,085 (as of Dec 2020)



Key Outcomes

● Season 1 (2011-2020) ● Season 2 (2021-2030, as of 2025)

Property Management

Cumulative assets



Approved Drug by

FDA / EMA




MFDS



Licensing Deals

New licenses



Biodollars licensing deals




● Exchange Rate: USD 1 = KRW 1,085 (as of Dec 2020)

● Exchange Rate: USD 1 = KRW 1,400 (as of Feb 2026)


Pipeline Overview

Total Of 553 Projects

KDDF assets by stage, indication



KDDF assets by modality, indication



How KDDF BD Creates Global Partnering: Five Strategic Pillars

- BD programs**

Curated Deal-Ready Portfolio Strategically selected KDDF-supported projects, positioned for co-development, licensing, and investment.
- BD Consulting**

Providing structured BD consulting to position KDDF-backed projects for co-development, licensing, and global partnering.
- Education**

Building practical global BD capabilities through hands-on training and real-world partnering exposure.
- Investment Enablement**

Enhancing investment readiness through asset valuation and structured access to global investors via partnering platforms.
- Partnering**

Connecting KDDF-backed institutions with global pharma and investors through curated platforms and ongoing partnering opportunities.

 - Annual events held in Seoul, Korea.



Interested in connecting with KDDF portfolio institutions or learning more? kddf_bd@kddf.org

Pipeline Details

As of December 2025

Oncology



Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Antibody								
ADC	Cancer	PRND (Doppel)	█				Seoul National University	RS-2021-DD116146
	Glioblastoma, Bladder cancer	FGFR3	█	█	█		AimedBio, Inc.	RS-2021-DD118828
	Gastrointestinal stromal tumor	cKIT (stem cell factor receptor, CD117)	█	█	█	█	Novelty Nobility Inc.	RS-2021-DD118912
	Rare cancer	Delta-Like Ligand 3 (DLL3)	█	█			IntoCell	RS-2021-DD120990
	Solid Tumor	TROP2 (tumor associated calcium signal transducer 2)	█	█	█	█	LigaChem Biosciences, Inc.	RS-2021-DD121148
	NSCLC	B7-H3	█	█	█	█	IntoCell	RS-2022-DD124206
	Gastric cancer, Gastroesophageal junction edema cancer	CLDN18.2	█	█	█	█	AbTis Co., Ltd.	RS-2023-00219493
	Bladder cancer, Glioblastoma	FGFR3 (Fibroblast Growth Factor Receptor 3)	█	█	█	█	AimedBio, Inc.	RS-2023-00282706
	Solid tumor	CD171 (L1CAM)	█	█			APITBIO Inc.	RS-2024-00338745
	AML	GSPT1	█	█	█		Therapex Co., Ltd.	RS-2024-00443425
	NSCLC	cMET	█	█	█	█	Chong Kun Dang pharmaceutical Corp.	RS-2024-00442212
	Metastatic breast cancer	HER3	█	█			IntoCell	RS-2024-00461865
	SCLC, GIST	c-Kit	█	█	█	█	Novelty Nobility Inc.	RS-2024-00461295
	Osteosarcoma, Solid Cancer	LRRC15	█	█			Edisbiotech. Co., Ltd	RS-2025-02183052

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
ADC	PDAC	CDCP1	█	█			Novelty Nobility Inc.	RS-2025-02192979
	Solid tumor	Target A	█	█	█	█	AimedBio, Inc.	RS-2025-02213655
	HCC & SCLC	***	█	█	█		Boostimmune	RS-2025-25445446
	Solid tumor	NAMPT	█	█	█		Samjin Pharmaceutical Co.,Ltd.	RS-2025-25454767
	Solid tumor	undisclosed	█	█	█	█	AimedBio, Inc.	RS-2025-25455321
BsAb	non-Hodgkin lymphoma, Chronic lymphocytic leukemia	CD20 and CD55	█				Korea University	RS-2021-DD115589
	Solid Tumor	B7-H4 (VTCN1) and 4-1BB	█	█	█	█	ABLBio	RS-2021-DD118355
	NSCLC	EGFR (Epidermal growth factor receptor) and cMET (Mesenchymal-epithelial transition factor)	█	█	█	█	Chong Kun Dang pharmaceutical Corp.	RS-2021-DD118094
	Solid Tumor	Single-regulatory protein α [SIRPα] and Programmed cell death-ligand 1 [PD-L1]	█				PharmAbcine Inc.	RS-2021-DD120856
	Solid Tumor	Programmed Death-Ligand 1 [PD-L1] and Cluster of Differentiation 3 [CD3]	█	█			MustBio, Inc.	RS-2021-DD120875
	Colorectal cancer	Human Leukocyte Antigen G (HLA-G) and CD3	█	█	█		Y-Biologics	RS-2021-DD121326
	Triple-Negative Breast Cancer	PD-L1 and CD47	█	█	█	█	ImmuneOncia Therapeutics	RS-2021-DD121388
	NSCLC, Lung cancer, Colorectal cancer, Gastric cancer, Triple-Negative Breast Cancer, Ovary cancer	LAG-3, PD-L1	█	█	█	█	ABLBio	RS-2021-DD120862
	Cancer	Complement C4d	█				Seoul National University	RS-2022-DD123825
	Triple-Negative Breast Cancer	CD73 & CD47	█				AprilBio Co., Ltd.	RS-2022-DD124111
	Solid Tumor	Programmed Death-Ligand 1 [PD-L1] and Interleukin-2 [IL-2]	█	█	█		MustBio, Inc.	RS-2022-DD123812
Solid Tumor	B7 Homolog 3 (B7-H3) and TGFβ	█	█	█		Theranotics	RS-2022-DD124303	

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
BsAb	TNBC, NSCLC, PC	DDR1 and TGF-β	█				POSTECH	RS-2023-00258678
	TNBC	Trop-2, Nkp46 and CD16A	█				KOREA UNIVERSITY	RS-2024-00337233
	Solid Cancer	Programmed Death-Ligand 1 [PD-L1] and *** [***]	█	█			GI Innovation, Inc	RS-2024-00461392
	Solid tumor	PD-1, IL-2 receptor in activated T cells	█	█	█	█	MustBio, Inc.	RS-2024-00459772
	Cancers with EGFR overexpression (such as colorectal cancer, non-small cell lung cancer, head and neck cancer, glioblastoma, and breast cancer)	EGFR	█				Seoul National University R&DB Foundation	RS-2025-02172968
	CEACAM5 positive solid tumor	CD3xCEACAM5	█	█	█		DAAN Biotherapeutics Inc.	RS-2025-02223296
	CRC, G/GEJ adenocarcinoma Cervical cancer	PD-1, VEGF, CTLA-4	█	█			Onogene Biotechnology	RS-2025-25447260
	NSCLC	TROP2 x PD-L1 x CD3	█	█			ARKGEN BioScions	RS-2025-25450700
	PDAC (Gateway to NSCLC, TNBC, and immune-excluded/fibrotic solid tumors)	PD-L1, VEGF-A, PLGF	█	█	█	█	Panolos Bioscience Inc.	RS-2025-25455606
	1st indication: HER2-positive Biliary Tract Cancer Other Indications: HER2-expressing solid tumors	HER2/4-1BB	█	█	█	█	Yuhan Corp.	RS-2025-25454580
Fusion protein	TROP2-positive solid cancer, Antibody-drug conjugates refractory/resistant patient	TROP2 Type I interferon IFNAR1/2	█	█			Abion, Inc.	RS-2025-02213236
mAb	Metastatic colorectal cancer	Extracellular Matrix Protein	█				Asan Medical Center	RS-2021-DD115940
	Metastatic malignant melanoma	ONCOKINE-2 (OK-2)	█				Korea University	RS-2021-DD116690
	Solid Tumor	TIGIT (T cell immunoreceptor with Ig and ITIM domains)	█	█	█		HanAll Biopharma	RS-2021-DD118279
	NSCLC	V-domain Ig Suppressor of T cell Activation (VISTA)	█	█	█	█	PharmAbcine Inc.	RS-2021-DD118786

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
mAb	Esophageal squamous cell carcinoma, Triple-Negative Breast Cancer, PTK7 expression cancer	Protein Tyrosine Kinase 7 [PTK7]	█	█			Yonsei University	RS-2021-DD121165
	Lung cancer	ONCOKINE-1	█	█			NEX-I	RS-2021-DD121304
	Lung cancer	DDOST (membrane protein)	█	█			Hanyang University	RS-2021-DD121345
	Lung cancer, Colorectal cancer, Breast cancer	CD300c	█	█	█	█	CentricsBio	RS-2021-DD121403
	Squamous cell carcinoma, Renal cell carcinoma, other solid tumor	Programmed cell death protein 1 (PD-1)	█	█	█	█	Y-Biologics	RS-2021-DD121392
	Cancer cachexia	GFRAL receptor	█	█	█		TroyY	RS-2022-DD123929
	Lung cancer	CMG	█	█	█	█	Wellmarkerbio	RS-2022-DD123939
	NSCLC	Transmembrane protease serine 4 (TMPRSS4)	█				KRIBB	RS-2022-00166100
	Solid Tumor	***** protein abundantly present in the bone metastasis microenvironment	█				Cellus, Inc.	RS-2022-00166371
	Solid Tumor	Tumor-associated macrophage	█	█			AimedBio, Inc.	RS-2022-00166068
	NSCLC	Chitinase-3 Like-Protein-1 (CHI3L1, YKL-40)	█	█			Senelix Co., Ltd.	RS-2022-00166446
	Solid Tumor	CNTN4 (Contactin-4)	█	█	█	█	Genome& Company	RS-2022-00166157
	Solid cancer	APP (Amyloid Precursor Protein)	█	█			Genome& Company	RS-2023-00217717
	Solid Cancer	Translationally controlled tumor protein (TCTP)	█	█	█		Boostimmune	RS-2023-00217478
	CLDN3hi solid cancer	Claudin-3 (CLDN3)	█	█	█		Abion, Inc.	RS-2023-00218182
N/A	A molecule that specifically expressed within tumor microenvironment in response to hypoxia	█	█			Seoul National University	RS-2023-00258823	
Melanoma	Interleukin 36 receptor	█				DGIST	RS-2023-00283446	
Cancer	PSMA (Prostate specific membrane antigen)	█	█			AbClon Inc.	RS-2023-00283056	

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
mAb	Cancer	CD33					Centenaire Biosciences, Inc.	RS-2023-00283660
	breast cancer, gastric cancer	HER2					Centenaire Biosciences, Inc.	RS-2024-00336882
	MSS CRC	TCTP					NEX-I	RS-2025-02213729
	TNBC	CTHRC1					Prestige Biopharma IDC	RS-2025-25444331

Cell Therapy

CAR-NK	Blood Cancer	CD5					KRIBB	RS-2021-DD115639
	Relapsed and Refractory Pancreatic cancer	Endoglin (CD105)					KIST	RS-2022-00166088
	B-cell lymphoma	CD19					GC Cell	RS-2024-00463361
	NK & T Cell Lymphoma	CD5					GC Cell	RS-2024-00508039
	Glioblastoma	GD2					Vigencell	RS-2025-25455212
CAR-T	Blood cancer	Universal system					KRICT	RS-2021-DD115994
	Solid Tumor	B7-H3					Seoul National University	RS-2021-DD116022
	Blood tumor	CD40					TICAROS	RS-2021-DD118773
	Non-small cell lymphoma	CD19-positive B cell lymphoma					Curocell, Inc.	RS-2021-DD118452
	Ovary cancer	L1 cell adhesion molecule (L1CAM, CD171)					Cartexell Inc.	RS-2022-DD124046
	Non-Hodgkin lymphoma	CD19					AbClon Inc.	RS-2022-DD123764
	Glioblastoma	IL13Rα2					CellabMED, Inc.	RS-2022-DD128914
	Ovarian cancer	Mesothelin (MSLN)					CellenGene	RS-2023-00217215
	B cell lymphoma	Cluster of Differentiation 19 (CD19)					TICAROS	RS-2023-00258721
	Solid Tumor	IL-21					Seoul National University	RS-2023-00282907
	Solid tumor	HLA-G (human leukocyte antigen G)					HK inno.N	RS-2023-00282541
	Liver cancer	Glypican-3 (GPC3)					Eutilex Co.,Ltd.	RS-2023-00283610
	MUC1 positive solid cancer	MUC-1 (Mucin-1)					TICAROS	RS-2024-00337759

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
CAR-T	B-cell lymphoma	CD19					AbClon Inc.	RS-2024-00332815
	Solid tumor (Ovarian Cancer)	EphA2 (Ephrin receptor A2), PD-L1 (Programmed cell death-ligand 1)					VAXCELL-BIO CO.,LTD.	RS-2024-00341192
	Multiple Myeloma	BCMA					nSAGE	RS-2025-25454748
Other-CT	Glioblastoma	Thymidylate synthase					CELLeBRAIN	RS-2022-00165974
	Liver cancer	N/A					Therabest Co., Ltd	RS-2023-00283732
	recurrent glioblastoma	N/A					CHA Biotech Co., Ltd	RS-2024-00334310
	HCC	NK-sensible Solid tumor					TSD Life Sciences	RS-2025-02213692
	Ovarian cancer	T Cell					CHA Biotech Co., Ltd	RS-2025-02213314
TCR-T	Multiple Myeloma	BCMA					VAXCELL-BIO CO.,LTD.	RS-2025-02223662
	HPV16/18 positive HNSCC	HPV16/18 E6, E7 protein					Cellid	RS-2025-25451121
	Solid Tumor	Patient-specific Neoantigen (NeoAg)					NeogenTC	RS-2022-DD124076
	EGFR L858R mutant lung cancer	EGFR mutant neoantigen (peptide-MHC)					DAAN Biotherapeutics Inc.	RS-2024-00336489

Gene & Nucleic acids

Aptamer	Ovary cancer	Tumor-specific ALCAM protein					HiCELL Tech, Inc.	RS-2022-DD128867
	Triple-Negative Breast Cancer	Nucleolin					Interoligo Corporation	RS-2022-DD128903
	Solid Tumor	CD25 (Regulatory T cell)					APTAMER Sciences, Inc.	RS-2022-00166270
	Ovarian cancer	ALCAM					HiCELL Tech, Inc.	RS-2025-02223684
ASO	Liver cancer	Let-7i-5p					NEORNAT Inc.	RS-2023-00217374
	Cancer [Pancreatic cancer, SCC (Squamous cell carcinoma), Lung cancer]	Dual action [CHICL1 (Chitinase3 Like Protein1) & PD-L1 inhibitor]					Autotelic Bio Inc.	RS-2025-02213057
GT-Virus vec.	Cancer	Universal					KRICT	RS-2025-02223194
	Glioblastoma (GBM)	hTERT mRNA					Rznomics inc.	RS-2025-02213273

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
GT-Virus vec.	Ovary cancer	Epithelial Cell Adhesion Molecule (EpCAM)					GENCELLMED INC.	RS-2021-DD120799
	Pancreatic cancer, Liver cancer	N/A					Yonsei University	RS-2021-DD120840
	Glioblastoma	Proliferating tumor cells					artiCure	RS-2022-DD124332
	Hepatocellular Carcinoma	CR-P1					CUROGEN TECHNOLOGY	RS-2024-00337392
	Ovarian cancer	Epithelial Cell Adhesion Molecule (EpCAM)					GENCELLMED INC.	RS-2024-00332252
	Glioblastoma	Proliferating tumor cells					articure	RS-2024-00338747
mRNA	B cell lymphoma	CD20/NK cell activating receptor					De novo Biotherapeutics	RS-2023-00258675
	Solid Tumor	Tumor specific neoantigens predicted by a GENINUS platform based on binding affinity between TCR and pMHC					GENINUS INC.	RS-2023-00284167
	TNBC	Tumor specific neoantigens predicted from deep learning platform technology					PentaMedix	RS-2024-00443388
	HNSCC	EGFR					Sungkyunkwan University (Research Business Foundation)	RS-2025-02213480
	NSCLC	pan-KRAS					KIST	RS-2025-25452986
	NSCLC, SCLC	SOX2 (Sex-determining region Y-box 2)					Genexine, Inc.	RS-2024-00337873
	Other-GT	Pancreatic Cancer and Prevention of Its Metastasis	hTERT					POSVAX Co., LTD.
RNA therapies	Solid Tumor	1) TLR9 (Toll-Like Receptor 9) 2) IDO1 (Indoleamine 2,3-Dioxygenase 1)					Lemonex Inc.	RS-2022-DD124062
	Bladder cancer, Head and neck cancer, Pancreatic cancer	mTOR, Stat3					Curigin Co., Ltd.	RS-2022-DD124198
	Ovarian cancer	cMyc/BCL2					Curigin Co., Ltd.	RS-2023-00219308
	Pediatric brain tumor	BRAF mRNA					Sovargen	RS-2023-00258484
	Pancreatic cancer	Pancreatic cancer patients who have been identified as having a KRAS/G12D mutation					Exollence Co., Ltd.	RS-2023-00282594














Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
RNA therapies	TNBC	N/A					NA Vaccine Institute	RS-2025-02213626
Others-Bio.								
Exosome	Acute Myeloid Leukemia	aGC-loaded ECVN of AML					Seoul National University R&DB Foundation	RS-2022-00165569
Other-B	Pancreatic cancer, Liver cancer	Fas-associated factor 1 (FAF1)					ChungNam National University	RS-2021-DD115490
	Solid Tumor	Cancer antigen-specific CD8+ T cells					Yonsei University	RS-2021-DD121415
	Colorectal cancer	N/A					CNCure biotech, Inc.	RS-2022-DD128973
	Solid Tumor	FlaB, ClyA					CNCure biotech, Inc.	RS-2022-00167101
	non-Hodgkin lymphoma	N/A					Progeneer, Inc.	RS-2022-00166284
Other-B	HER2 low Gastric Cancer	HER2 overexpressed solid cancers, HER2 low (mild/moderate expressed) solid cancers					KMD BIO LTD.	RS-2024-00333872
	NHL (non Hodgkin Lymphoma)	B-cell receptor variable region (idiotype)					Progeneer, Inc.	RS-2025-02122974
Others-Synth.								
MRI contrast agent	Diagnostic	N/A					BL Melanis	RS-2022-00165594
Other-S	Colorectal cancer, Breast cancer, Ovary cancer, Pancreatic cancer	Cancer biomarker (Cathepsin B)					Ewha Womans University	RS-2021-DD116372
	Glioblastoma	Translocator proteins overexpressed cancer; Glioblastoma					Seoul National University	RS-2022-DD128967
	Malignant tumor	N/A					Yonsei University	RS-2022-DD128984
rProtein								
Fusion protein	Kidney cancer, Skin cancer	Teff/NK cell					GENUV	RS-2021-DD121044
	Advanced or Metastatic Solid Tumor	CTLA-4 and IL-2Rβ					GI Innovation, Inc	RS-2022-DD124313
	Colorectal cancer	EGFR expressing in cancer and 4-1BB on cancer reactive T cell					CTCELLS	RS-2022-00166009












Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Fusion protein	HER2+ tumor	HER2					GenoPharm, Inc.	RS-2022-00166539
	Solid Tumor	FAP, IL-12					KANAPH Therapeutics, Inc	RS-2022-00166851
	Solid Tumor	Anti-CD73-IgG4 Fc-IL-2v3					GI Innovation, Inc	RS-2022-00166700
	NSCLC, Melanoma	PD-L1, TIGIT					Cellemedy	RS-2023-00218402
	Metastatic Melanoma	CD8+ T/NK cell					GI Innovation, Inc	RS-2024-00459844
	Solid tumor	PD-1, VEGF, IL-2R					MustBio, Inc.	RS-2025-02172980
	High-risk HPV infection-induced cervical intraepithelial neoplasia (CIN) and early-stage cervical cancer	Dendritic cells (CD11c ⁺ DCs) via dual activation of TLR5/NLRC4 pathways using HPV16/18/52/58/33/45 E7 ΔNLS antigens					Chonnam National University R&BD Foundation	RS-2025-25446859
	Solid tumors	TGF-β and ***					MedPacto, Inc.	RS-2025-25449690
PDC	Solid Tumor (EGFR overexpression)	EGFR-overexpressing tumor cells compared to normal cells					ProEn Therapeutics, Inc	RS-2022-00166310
	mCRC	EGFR					ProEn Therapeutics, Inc	RS-2025-02223464
Peptide	Pancreatic cancer, Lung cancer	Cancer cells with KRAS G12 mutations					NA Vaccine Institute	RS-2021-DD121289
	Colorectal cancer	Tumor exosome					Sungkyunkwan University	RS-2022-DD128953
	Lung cancer	Tumor specific neoantigens predicted from deep learning platform technology					PentaMedix	RS-2022-00166187
	GBM Glioblastoma, multifocal	CMV-positive cancer cells					NA Vaccine Institute	RS-2024-00337146
rProtein	Cancer	Immune Checkpoint Inhibitors (Cancer cells) & Cytokine Receptor (Immune Cells)					BIOOnSYSTEMS	RS-2021-DD121011
	Pre-treated metastatic Pancreatic ductal adenocarcinoma (PDAC)	Retinoid (retinol and retinoic acid) in activated stellate cells					Senelix Co., Ltd.	RS-2022-DD128861
	Renal cell carcinoma, melanoma	IL-2Rβ and IL-2Rα					Hanmi Pharm. Co., Ltd.	RS-2022-00165557

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
RPT								
RPT	Prostate cancer	Prostate specific membrane antigen (PSMA)					CellBion Co., Ltd.	RS-2021-DD118377
	Prostate cancer	PSMA					FutureChem Co., Ltd.	RS-2021-DD121273
	ccRCC	CAIX (Carbonic anhydrase IX)					C-BIOMEX	RS-2023-00218641
	Castration-resistant prostate cancer	Prostate Specific Membrane Antigen (PSMA)					FutureChem Co., Ltd.	RS-2023-00218051
	Ovarian cancer	Folate Receptor-α (FR-α)					ZTI BIOSCIENCES, Inc	RS-2024-00337888
	Melanoma	Melanin					CNCure biotech, Inc.	RS-2025-25454797
	Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Prostate-Specific Membrane Antigen (PSMA)					CellBion Co., Ltd.	RS-2025-25454770
Small molecules								
Small molecules	Cancer	N/A					GIST	RS-2021-DD115879
	Chronic Myelogenous Leukemia	BTK (C481S)					Medytox Inc.	RS-2021-DD118854
	Breast cancer	Human Epidermal Growth Factor Receptor 2 (HER2)					B2SBio Inc.	RS-2021-DD118858
	Triple-Negative Breast Cancer, CDK4/6 Inhibitor resistance solid cancer	Monopolar Spindle 1 (Mps1/TTK)					Voronoj, Inc	RS-2021-DD118198
	NSCLC	Epidermal Growth Factor Receptor (EGFR)					Bridge Biotherapeutics, Inc	RS-2021-DD118911
	Triple-Negative Breast Cancer	Histone deacetylase 6/8 (HDAC 6/8)					Sookmyung Women's University	RS-2021-DD120822
	Chronic Myelogenous Leukemia, Acute myelogenous leukemia	3-hydroxy-3-methylglutaryl-CoA					Samsung Medical Center	RS-2021-DD120834
	Lung cancer	Ubiquitination pathway: UBA6 (E1) - USE1 (E2)					KRICT	RS-2021-DD120986
	Solid Tumor	GLS1					KRICT	RS-2021-DD121124

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Small molecules	Breast cancer	Tribbles homolog 2 (TRIB2)					Genesen Co,Ltd	RS-2021-DD121151
	Colorectal cancer	USP21					K-MEDI hub	RS-2021-DD121161
	Solid Tumor	STING (stimulator of interferon genes)					SPARK Biopharma	RS-2021-DD120924
	Acute myelogenous leukemia	pan-proviral insertion in murine (PIM) kinase					Jeil Pharmaceutical Co., Ltd.	RS-2021-DD120716
	Resistant cancer	Undisclosed Target					PimedBio	RS-2021-DD120835
	Malignant tumor	Enhancer of Zeste Homolog 1 and 2 (EZH1 and EZH2)					Hanmi Pharm. Co., Ltd.	RS-2021-DD120985
	Triple-Negative Breast Cancer	Ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1)					KIST	RS-2022-DD123827
	Solid Tumor	G9a (Histone methyl transferase 2, EHMT2)					Asan Medical Center	RS-2022-DD123789
	Breast cancer	MASTL					KIRAMS Oncord bio	RS-2022-DD123956
	Colorectal cancer, Lung cancer, Pancreatic cancer	ULK1 (Unc 51-like autophagy activating kinase), serine/threonine protein kinase					TXINNO Bioscience	RS-2022-DD124038
	NSCLC, Colorectal cancer, Head and neck cancer	SHP2 (Src homology region 2-containing protein tyrosine phosphatase 2)					KANAPH Therapeutics, Inc	RS-2022-DD123830
	Triple-Negative Breast Cancer	TTK (MPS1)					KRICT	RS-2022-DD129052
	Colorectal cancer (KRAS mutation)	AIMP2-DX2 (DX2)					Zymedi	RS-2022-DD129034
	Colorectal cancer	ENPP1					TXINNO Bioscience	RS-2022-DD128818
	Triple-Negative Breast Cancer	STAT3					JW Pharmaceutical	RS-2022-DD128901
	Advanced Solid Tumor	Aryl hydrocarbon Receptor (AhR)					DONG-A ST	RS-2022-DD128959
	NSCLC (EGFR mutation)	EGFR					Voronoj, Inc	RS-2022-DD129011
	Solid Tumor	STING					KIST	RS-2022-00166522
	Malignant tumor	FOXM1					Korea University Research & Business Foundation	RS-2022-00167112

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Small molecules	Colorectal cancer	GCN2					1ST Biotherapeutics, Inc.	RS-2022-00165544
	Brain cancer, Lung cancer	HPK1/MLK3					MD Biolab Co.,Ltd	RS-2022-00165566
	Prostate cancer	PIP5K1α					TSD Life Sciences	RS-2022-00165973
	Multiple Myeloma	UCHL5					KRIBB	RS-2022-00166286
	Liver cancer, MASH	FLT3/VEGFR2/KIT/PDGFRβ					Etnova Therapeutics Corp.	RS-2022-00165725
	Glioblastoma	SREBP1-dependent lipid metabolism					MEDIFIC, Inc.	RS-2022-00166323
	Glioblastoma	PRMT5					SK Biopharmaceuticals	RS-2022-00165541
	Solid Tumor	TGFβR1					TiumBio Co., Ltd.	RS-2022-00167091
	polycythemia vera	Heme-regulated inhibitor (HRI)					NexThera Co., Ltd.	RS-2023-00218778
	NSCLC	EGFR					HK inno.N	RS-2023-00217095
	KRAS-mutated solid cancer (Pancreatic, Lung, Colon cancer)	SOS1 (Son of sevenless 1)					Jeil Pharmaceutical Co., Ltd.	RS-2023-00217674
	Breast cancer, Colon cancer	HER2 (ERBB2) and HER mutants					Voronoj, Inc	RS-2023-00217541
	pancreatic cancer	Sirt6					SCBIO	RS-2023-00218894
	Colorectal cancer	Mutant CRG Kinase					Wellmarkerbio	RS-2023-00219060
	Solid Cancer	Rev1					D5 Therapeutics	RS-2023-00258885
	Solid Cancer	FoxM1 (Forkhead box M1)					KRICT	RS-2023-00258901
	TNBC	HGF, HER2, TROP2, EGFR					Pinotbio, Inc.	RS-2023-00258783
	TNBC	Antigen present on the surface of cancer cells (Ex. HER2, HER3, Nectin-4, Claudin 18.2, Trop-2, EGFR etc.)					AbTis Co., Ltd.	RS-2023-00259367
	Solid Cancer	PD-L1 protein expressed on cell surface					llab	RS-2023-00258167
	Castration-resistant prostate cancer	Androgen receptor (AR) and AR-V7					Incurix Co., Ltd.	RS-2023-00258594

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Small molecules	Acute Myeloid Leukemia	Signal Transducer and Activator of Transcription 5 and 3 (STAT5 and 3)					JW C&C Research Laboratories	RS-2023-00258859
	NSCLC, Melanoma	SMARCA2					Hyundai Pharm	RS-2023-00259457
	Solid Tumor	VRK1					KRICT	RS-2023-00283832
	Cancer	SIRT7					KRICT	RS-2023-00283539
	Cancer	Myc (c-Myc/L-Myc/N-Myc)					Incurix Co., Ltd.	RS-2023-00283511
	Solid tumor	PKMYT1					Voronoi, Inc	RS-2023-00283890
	Solid tumor	SOS1					Cyrus Therapeutics	RS-2023-00283208
	Solid tumor	ENPP1					TXINNO Bioscience	RS-2023-00282830
	Solid tumor, NSCLC	c-MET					Abion, Inc.	RS-2023-00284103
	incurable cancer	Mitochondrial Glutamine Transporter					Yonsei University	RS-2024-00334337
	gastric cancer, colon cancer	MAST3					KRICT	RS-2024-00336646
	Glioblastoma, Liver cancer	WNK3 (WNK lysine deficient protein kinase 3)					CHECKMATE THERAPEUTICS INC.	RS-2024-00337810
	KRAS G12X-mutant cancer	Discoidin Domain Receptor 1 (DDR1)					CUREVERSE	RS-2024-00336018
	Cancers (NSCLC, melanoma) with high tumor mutational burden	PI3Kδ & CSF1R					Chung Ang University	RS-2024-00337284
	Lung cancer, Solid cancer	CMTM6					Kangwon National University	RS-2024-00338105
	Metastatic Castration Resistant Prostate Cancer	X-Box-binding Protein 1 splicing form (XBP1s)					JW C&C Research Laboratories	RS-2024-00333115
	Cancer (BRCA Mutant)	USP1					AIGEN Sciences	RS-2024-00338363
	Colorectal cancer	CD39					SCBIO	RS-2024-00336376
	Ovarian cancer, Endometrial cancer, Renal cell carcinoma	HPK1 kinase inhibitor					1ST Biotherapeutics, Inc.	RS-2024-00332279
	Solid tumor (ovarian, colorectal, melanoma, etc.)	Novel transcriptional regulator function in both cancer and immune cells					Samjin Pharmaceutical Co.,Ltd.	RS-2024-00332412

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Small molecules	Anaplastic Thyroid Cancer	SHMT2 (serine hydroxymethyltransferase 2)					KRICT	RS-2024-00460989
	Metastatic colorectal cancer	Recurring and metastatic colorectal solid tumor					Chosun University	RS-2024-00463393
	lung cancer, colon cancer	DNA AP-site					KAIST	RS-2024-00463605
	Breast cancer (HR+ HER2-)	CDK7					Cyrus Therapeutics	RS-2024-00463231
	Solid cancer (NF2 mutant, EGFR mutant, KRAS mutant)	TEAD1					Daewoong Pharmaceutical	RS-2024-00462280
	Solid cancer	PARP-1 selective inhibitor					Digmbio	RS-2024-00460284
	PDAC	NUAK1					Korea Institute of Radiological and Medical Sciences	RS-2025-02213330
	NEPC	NEDDylation					KRICT	RS-2025-02223190
	Lung, pancreas, colon cancer	KRAS					Idience Co., Ltd.	RS-2025-02183021
	BRCA(-) Cancers, HRD(+) Cancers (Breast, Ovarian, etc.)	USP1					Avelos Therapeutics, Inc.	RS-2025-02213433
	NSCLC	c-MET					CMG Pharmaceutical Co.Ltd	RS-2025-02213745
	Breast cancer, Ovarian cancer	USP1					Hyundai Pharm	RS-2025-02223126
	Ovarian cancer	Polθ					Daewoong Pharmaceutical	RS-2025-02213327
	Small Cell Lung Cancer	N/A					SN BioScience Inc.	RS-2025-02073050
	NSCLC	EGFR					J INTS BIO	RS-2025-02183074
	Solid tumor	HER2					Yuhan Corp.	RS-2025-02213533
	PCNSL	BTK, TEC					NOBO Medicine, Inc.	RS-2025-02212979
	RCC	*****					Sogang University	RS-2025-25452008
	AML	NMT					INNOVO Therapeutics	RS-2025-25444455
	PDAC	ULK1					Cowellbiodigm	RS-2025-25454972

Drug Class	Indication	Targets	Development Stage				Company	Project ID	
			Discovery	Pre	Ph1	Ph2			
Small molecules	TNBC	PRDX2					VasThera Co., Ltd.	RS-2025-25454944	
	Esophageal cancer	Photodynamic therapy					HANLIM PHARM.CO.,LTD	RS-2025-25454976	
	KRAS mutated cancers (NSCLC, CRC, PDAC)	SOS1					Jeil Pharmaceutical Co., Ltd.	RS-2025-25455195	
	CRC, GC, Sarcoma, TNBC, AML etc.	MASTL					Avelos Therapeutics, Inc.	RS-2025-25446915	
TPD									
Mole. glue	Acute Myeloid Leukemia	CK1α					Pin Therapeutics	RS-2022-00166852	
	SCLC, AML	GSPT1					Cyrus Therapeutics	RS-2023-00282972	
	Solid tumor (NSCLC, Melanoma, TNBC)	IKZF2 (Helios)					KRICT	RS-2024-00332418	
	ACC, CRC	CK1α					Pin Therapeutics	RS-2024-00441932	
	MSI-H/dMMR Colon Cancer	CBL-B					Immuse Therapeutics	RS-2024-00460474	
	Colorectal cancer	TEAD Interface3					KRICT	RS-2025-02223174	
	TNBC	PLK1					AevisBio, INC.	RS-2025-02212974	
	Multiple myeloma Lung cancer Prostate cancer	GSPT1					Protier Biotech	RS-2025-25444435	
	Other-TPD	castration-resistant prostate cancer	Androgen receptor					KRICT	RS-2024-00332392
		Breast cancer (ER-positive)	Estrogen Receptor					KRICT	RS-2024-00459720
Breast Cancer		PI3Kα					MagicBullet Therapeutics	RS-2024-00462810	
mCRC, NSCLC, HNSCC		EGFR					Ewha Womans University	RS-2025-02223093	
solid tumors expressing mutant growth factor receptors (GFRs)		MYO1D/GFRs					VAXCELL-BIO CO.,LTD.	RS-2025-25444375	
PROTAC		NSCLC	Multiple EGFR mutants including C797S mutation					Cyrus Therapeutics	RS-2021-DD120845

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
PROTAC	Pancreatic cancer	Immunosuppressive tumor-associated macrophage					Seoul National University	RS-2022-DD128974
	NSCLC	PLK1					DANDICURE, Inc.	RS-2022-DD128873
	NSCLC (EGFR mutation)	NSCLC with EGFR single, double and triple mutation, Osimertinib-resistant EGFR mutated NSCLC (C797S double and triple mutation)					J2H Biotech	RS-2022-DD129020
	NSCLC	PLK1 (Polo like kinase 1)					UPPTHERA, Inc	RS-2022-00167113
	Cancer	AURKA (Aurora kinase A)					UPPTHERA, Inc	RS-2023-00217986
	Acute myeloid leukemia, AML	FLT3 mutants resistant to the approved FLT3 inhibitor such as gilteritinib					Yonsei University	RS-2023-00218195
	Castration-resistant prostate cancer	Androgen receptor (AR)					Ubix Therapeutics, Inc.	RS-2023-00258142
	NSCLC	Mesenchymal-epithelial transition factor receptor (MET)					InnoCure Therapeutics Inc.	RS-2023-00259138
	NUT Midline Carcinoma	Bromodomain-containing protein 4-nuclear protein in testis (BRD4-NUT)					InnoCure Therapeutics Inc.	RS-2023-00282701
	KRAS mutant cancer (PDAC, NSCLC, CRC)	SHP2					Elgen Therapeutics Inc.	RS-2025-02202978
	AML/ALL	CDK6					Yonsei University, University-Industry Foundation	RS-2025-25452139
	Acute myeloid leukemia (AML)	FLT3					MagicBullet Therapeutics	RS-2025-25450363
	Relapsed/Refractory B-cell Malignancies	BTK/HCK/LYN					Ubix Therapeutics, Inc.	RS-2025-25454729



Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Antibody								
BsAb	Rheumatoid Arthritis, autoimmune diseases	OX40L and TNF					IMBiologics	RS-2022-DD124020
mAb	Paroxysmal nocturnal hemoglobinuria	C5					ImmunAbs, Inc.	RS-2021-DD118446
	Multiple Sclerosis	Human CD40					PB Immune Therapeutics	RS-2021-DD121355
	Asthma, Atopic dermatitis	TCTP/HRF					Ewha Womans University Industry-Academic Cooperation Foundation	RS-2022-DD128822
	Pemphigus	Human CD40					PB Immune Therapeutics	RS-2022-00165917
	Rheumatoid Arthritis	WARS1					MirimGene Co., Ltd.	RS-2022-00166575
	Atopic dermatitis	Immune cells overexpressing CD200R1					AimedBio, Inc.	RS-2023-00218545
	Rheumatoid Arthritis	sFasL					Seoul National University	RS-2023-00259272
	Autoimmune diseases	Human Complement C5					ImmunAbs, Inc.	RS-2023-00258444
	Asthma	FcεR1α (IgE receptor)					FatiAbGen Co., Ltd.	RS-2023-00284138
	Graft-versus-host disease	Novel immune modulatory proteins expressed on the surface of activated T cells					Sungkyunkwan University	RS-2024-00333055
Rheumatoid Arthritis, Multiple Sclerosis	PLGF (Placental growth factor)					Catholic University	RS-2024-00462449	
IBD	RESISTIN					KIM CELL&GENE	RS-2025-02132982	
Atopic Dermatitis	OX40					Centenaire Biosciences, Inc.	RS-2025-25453439	
Gene & Nucleic acids								
ASO	Inflammatory Bowel Disease (Ulcerative Colitis, Crohn's Disease)	NLRP3, CD47					SHIFTBIO.INC	RS-2025-02122993

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Others-Bio.								
Exosome	Inflammatory Bowel Disease	Caspase recruitment domain-containing protein-9 (CARD9)					ILIAS Biologics Inc.	RS-2022-DD128900
Microbiome	Ulcerative colitis	Inflammation-induced innate immunity					Liveome Inc.	RS-2023-00217138
	Rheumatoid Arthritis	Gut (Gut-joint axis)					BIFIDO Co., Ltd	RS-2023-00258617
	GvHD	Regulatory T cells					Liveome Inc.	RS-2024-00460623
Others-Synth.								
Nanoparticles	Psoriasis, Contact dermatitis	TLR4, CD44					Ajou University	RS-2021-DD120838
	Ischemia reperfusion injury	Reactive Oxygen Species (ROS)					BILIX	RS-2021-DD120815
rProtein								
Fusion protein	Rheumatoid Arthritis	TM4SF19 (Transmembrane 4 L six family member 19)					MedPacto, Inc.	RS-2023-00282595
	psoriasis, psoriatic arthritis	IL-17A, IL-17F and TNFα					CUROGEN TECHNOLOGY	RS-2024-00462095
Peptide	Atopic dermatitis	Formyl peptide Receptor 2 (FPR2)					Novacell Technology Inc.	RS-2021-DD120966
	Multiple Sclerosis	Formyl peptide receptor					Sungkyunkwan University	RS-2022-DD124051
	Multiple Sclerosis	****					KINE SCIENCES	RS-2025-25454784
rProtein	Inflammatory Bowel Disease, Systemic Lupus Erythematosus	Regulatory T cells					AprilBio Co., Ltd.	RS-2022-00165592
Small molecules								
Small molecules	Psoriasis	CR-E1 (pellino1)					CUROGEN TECHNOLOGY	RS-2021-DD116095
	Systemic Sclerosis	A strategy to selectively inhibit the SOS1/RAS signaling pathway					Kyungpook National University	RS-2021-DD116254
	Psoriasis, Rheumatoid Arthritis	Tyrosine Kinase 2 (TYK2)					Crystal Genomics, Inc.	RS-2021-DD115864
	Atopic dermatitis	Signal Transducer and Activator of Transcription 3 (STAT3)					JW C&C Research Laboratories	RS-2021-DD118071
	Ulcerative colitis	PYGL					INNOVO Therapeutics	RS-2021-DD118337

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Small molecules	Atopic dermatitis	Early Growth Response Gene-1 (Egr-1)	■				Konkuk University	RS-2021-DD120874
	Psoriasis, MASH	NLRP3 Inflammasome	■ ■				Ajou University	RS-2021-DD120963
	Inflammatory bowel disease, Rheumatoid arthritis, Psoriasis, Ankylosing spondylitis, Idiopathic pulmonary fibrosis, MASH	Pyruvate kinase M2 (PKM2)	■ ■ ■				Lmito Therapeutics Inc.	RS-2021-DD120810
	Ulcerative colitis, Crohn's disease	Undisclosed Target	■ ■				PimedBio	RS-2022-DD123818
	Crohn's disease	LRRK2	■ ■				Chung Ang University	RS-2022-DD129045
	Crohn's disease	Aryl hydrocarbon receptor	■ ■ ■ ■				Parenchyma Biotech	RS-2022-00165759
	Ulcerative Colitis	Not opened	■ ■ ■ ■ ■				INNOVO Therapeutics	RS-2022-00166802
	Systemic Sclerosis	STAT6	■				Catholic University	RS-2023-00217274
	Psoriasis	Peripheral cannabinoid receptor 1 (CB1R)	■				Ajou University	RS-2023-00217308
	Multiple Sclerosis	PKC η	■				Hanyang University	RS-2023-00217324
	Multiple Sclerosis	S1P1	■ ■ ■ ■				CUREVERSE	RS-2023-00217346
	Ulcerative colitis	15-PGDH	■ ■ ■				INNOVO Therapeutics	RS-2023-00258490
	Autoimmune diseases	The receptor-interacting serine/threonine-protein kinase 1 (RIPK1)	■ ■ ■				BiSiChem	RS-2023-00259271
	Atopic dermatitis	TSLP-TSLPR signal pathway	■ ■ ■ ■				AmtixBio	RS-2023-00258738
	Psoriasis	Interleukin-1 receptor-associated kinase (IRAK) 1/4	■ ■ ■				Dongwha Pharm	RS-2023-00284094
	Multiple sclerosis	Lipocalin-2 (LCN2)	■				K-MEDI hub	RS-2024-00335752
	Multiple sclerosis, RRMS	PKM2	■ ■				Hanyang University ERICA	RS-2025-02223325
	IBD	NLRP3	■ ■ ■				JMackem Co., Ltd	RS-2025-02173120
	Eosinophilic Esophagitis and Th2 Inflammatory Immune Diseases	STAT6	■ ■ ■				JW C&C Research Laboratories	RS-2025-02183026

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Small molecules	Atopic Dermatitis	EGR-1	■ ■ ■				AgeraMedi	RS-2025-02213190
	Psoriasis	TYK2	■ ■ ■				AZothBio, Inc.	RS-2025-02213331
	Chronic Urticaria	****	■ ■ ■ ■				Samjin Pharmaceutical Co.,Ltd.	RS-2025-02173007
	UC	JAK	■ ■ ■ ■				Omnimed	RS-2025-02223486
	cGVHD	Axl, Mer, CSF1R	■ ■ ■ ■ ■				Qurient Co., Ltd.	RS-2025-02213024
	inflammation and pain-related disorders	mPGES-1	■ ■ ■ ■				Kukje pharma	RS-2025-25454561
	Multiple Sclerosis	****	■ ■ ■ ■				Daewoong Pharmaceutical	RS-2025-25455086
	Inflammatory Bowel Disease (IBD); Ulcerative Colitis (UC) and Crohn's Disease (CD)	CR-E1	■ ■ ■ ■				CUROGEN Technology	RS-2025-25455442
	TPD							
PROTAC	Systemic Lupus Erythematosus	IRAK4	■ ■				Gachon University	RS-2023-00218618
	Atopic dermatitis (Skin immune disease)	STAT3	■ ■				Genexine, Inc.	RS-2025-25455457

Neurology



Drug Class	Indication	Targets	Development Stage				Company	Project ID	
			Discovery	Pre	Ph1	Ph2			
Antibody									
mAb	Myasthenia gravis	Disclosure after confidentiality agreement	■	■	■		Medytox Inc.	RS-2023-00283006	
	Myasthenia gravis	Human Complement 5 (C5)	■	■	■	■	ImmunAbs, Inc.	RS-2025-25454824	
Gene & Nucleic acids									
ASO	FCDII Refractory epilepsy	eIF4E	■	■	■	■	Sovargen	RS-2021-DD118363	
	Amyotrophic Lateral Sclerosis	Stathmin 2 (STMN2)	■	■			OliPass Corporation	RS-2022-DD123773	
	Parkinson's disease	TLR2 (Toll-Like Receptor 2)	■	■			SEASUN THERAPEUTICS	RS-2022-DD124261	
	Parkinson's disease	****	■	■	■	■	HLB Neurotope	RS-2025-02223597	
GT-Virus vec.	SMA	SMN2, SMN1	■				GenKOre	RS-2025-25454812	
	Rett syndrome	MeCP2	■	■			Rznomics inc.	RS-2021-DD121315	
	Neuropathic Pain	GTP cyclohydrolase 1 (GCH1)	■				Yonsei University	RS-2022-DD124122	
	Charcot-Marie-Tooth disease type 1A	Peripheral myelin protein 22 (PMP22)	■	■	■	■	ToolGen, Inc.	RS-2022-DD124286	
	Spinal cord injury	Astrocytes	■	■	■		Stand Up Therapeutics	RS-2022-00167083	
	Huntington's disease	HTT gene (CAG repeat expansion)	■				GenKOre	RS-2023-00259174	
	Amyotrophic Lateral Sclerosis	HGF/c-Met signaling pathway	■	■	■		Helixmith	RS-2023-00283601	
	Chronic Spinal Cord Injury	Non-neuronal cells	■	■	■	■	Stand Up Therapeutics	RS-2025-02173013	
	Other-GT	DM1	DMPK	■	■			NES Biotechnology	RS-2025-25455070
	RNA therapies	Pediatric epilepsy	Undisclosed	■	■	■		Sovargen	RS-2023-00282544

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Others-Bio.								
Exosome	Parkinson's disease	Mitochondria	■				Sungkyunkwan University	RS-2021-DD121228
Others-Synth.								
Nanoparticles	Cerebral infarction	ROS-related inflammation	■	■	■	■	Cenx Biotech Inc.	RS-2023-00284156
	Subarachnoid Hemorrhage	Reactive Oxygen Species (ROS)	■	■	■	■	Cenx Biotech Inc.	RS-2025-02183050
rProtein								
Peptide	Chronic Pain	TRPV1 channel	■	■			Gachon University	RS-2022-00167087
	Amyotrophic lateral sclerosis	Lysosome Activation	■	■	■		Zincure corp.	RS-2023-00218770
Small molecules								
Small molecules	Progressive supranuclear palsy, 4R tauopathies	4R tau oligomer	■	■			KIST	RS-2021-DD116285
	Parkinson's disease	LRRK2 (leucine-rich repeat kinase 2)	■	■	■		Whan In Pharm. Co., Ltd.	RS-2021-DD118454
	Major depressive disorder	α2 adrenergic antagonist and NDRI	■				Kyung Hee University	RS-2021-DD120983
	Parkinson's disease	Confidential	■				Hanyang University	RS-2021-DD121219
	Parkinson's disease	Apoptosis Signal-regulating Kinase (ASK1)	■	■			KRICT	RS-2021-DD121059
	Parkinson's disease	Novel TAS2R GPCR	■	■			Digmbio	RS-2023-00219269
	Amyotrophic Lateral Sclerosis	SOD1 misfolding/aggregation	■	■	■	■	PRG S&Tech Inc.	RS-2023-00258714
	Parkinson's disease	PIP5Ky	■				K-MEDI hub	RS-2023-00283494
	Parkinson's disease	c-Abl/LRRK2 dual inhibitor	■	■	■	■	1ST Biotherapeutics, Inc.	RS-2023-00283009
	Neurofibromatosis type 2	Oncopathogenic neo-TβR1-RKIP interaction	■	■	■	■	PRG S&Tech Inc.	RS-2024-00442484
	Parkinson's disease	Estrogen-related receptor gamma (ERRγ)	■	■			CHA University	RS-2024-00463446
	Parkinson's disease	Paraoxonase 2 (PON2)	■	■	■	■	Glacem Inc.	RS-2024-00459662
	Tuberous sclerosis complex (TSC)	Rheb	■				K-MEDI hub	RS-2025-02213662



Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Small molecules	Quantitative CT diagnosis of ischemic stroke	Fibrin	■	■			Seoul National University R&DB Foundation	RS-2025-02223267
	Stroke/Global Ischemia	MMP-9	■	■	■		Zincure corp.	RS-2025-02182973
	Neuropathic pain	AAK1	■	■	■		CIMPLRX Co. Ltd.	RS-2025-02213667
	Parkinson's disease	ASK1	■	■	■		Naason Science Inc.	RS-2025-02213938
	CMT1A	Oxido-reductase	■	■	■	■	Lmito Therapeutics Inc.	RS-2025-02073078
	Parkinson's disease	LRRK2	■	■	■	■	Novorex Inc.	RS-2025-02213047
	Osteoarthritis	TrkA	■	■	■	■	Mother's Pharmaceutical Co., Ltd.	RS-2025-02213103
	ALS	TDP43	■				KIST	RS-2025-25453059
	Parkinson's disease	FKBP (FK506-binding protein)	■	■	■		MolGenBio Co., Ltd.	RS-2025-25444385
	Parkinson's disease	Keap1-Nrf2 axis	■	■	■		SPARK Biopharma	RS-2025-25449417
	Parkinson's disease	TAS2R GPCR	■	■	■		DigmBio	RS-2025-25453249
	Charcot-Marie-Tooth disease	HDAC6	■	■	■	■	Chong Kun Dang	RS-2025-25454943
	Neuropathic Pain (PHN)	5-HT2AR, mGluR5	■	■	■	■	Vivozon	RS-2025-25454827
	TPD							
Mole. glue	Parkinson's disease	Neuroinflammation	■	■	■		AevisBio, INC.	RS-2024-00338017
Other-TPD	Parkinson's disease	α-synuclein aggregates	■				AUTOTAC Bio Inc.	RS-2022-00166787
	Parkinson's disease	α-synuclein	■	■			Prazer Therapeutics, Inc.	RS-2024-00445011
	Progressive supranuclear palsy	Tau	■	■			KRICT	RS-2025-02223246

Metabolic

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Antibody								
BsAb	Sarcopenic obesity & Metabolic dysfunction	Activin type 2 receptors (ActRII) and Myostatin	■	■			ProGen Co., Ltd.	RS-2025-02213767
mAb	MASH	Resistin	■	■			Seoul National University Hospital	RS-2021-DD116856
Gene & Nucleic acids								
GT-Virus vec.	MASH	CR-P1	■	■	■		CUROGEN TECHNOLOGY	RS-2021-DD118830
Other-GT	Obesity	White Adipocytes in Visceral Adipose Tissue and Fatty Acid Binding Protein (FABP4 & FABP5) Knockdown	■	■			Hanyang University	RS-2021-DD120715
RNA therapies	Obesity, type 2 diabetes	The primary targets of this therapy are FABP4 (Fatty Acid Binding Protein 4) and FABP5 (Fatty Acid Binding Protein 5), which are intracellular lipid chaperones.	■	■	■		Cursus Bio Inc.	RS-2024-00459648
	Patients with dyslipidemia who have a combination of high LDL-cholesterol and high triglycerides	PCSK9 and APOC3	■	■	■		Curigin Co., Ltd.	RS-2025-02213434
Others-Bio.								
Microbiome	Obesity	Microbial community	■	■	■		KoBiolabs Inc.	RS-2023-00219249
rProtein								
Fusion protein	MASH	TLR5	■	■	■		MediSpan Co., Ltd.	RS-2022-DD128921
	Obesity	GDF15 receptor agonist	■	■	■	■	Yuhan Corp.	RS-2022-DD128862
	Obesity, type 2 diabetes	GLP-1R and GLP-2R	■	■	■	■	ProGen Co., Ltd.	RS-2024-00335179
Peptide	MASH	CXCR7	■				Yonsei University, University-Industry Foundation	RS-2022-DD128985

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Peptide	MASH	GLP-1 and Glucagon receptor (Dual agonist)					D&D Pharmatech	RS-2025-02073063
rProtein	Acromegaly	Human growth hormone receptor antagonist					Alteogen	RS-2021-DD118039
	MASH	FGF21, GLP-1, GCG, α -cytokine					Onogene Biotechnology	RS-2021-DD118111
	Congenital hyperinsulinism	N/A					Hanmi Pharm. Co., Ltd.	RS-2021-DD118329
	MASH	Glucagon-like peptide-1 [GLP-1], Glucagon [GCG], Fibroblast growth factor21 [FGF21], and Interleukin-1 receptor antagonist [IL-1RA]					Onogene Biotechnology	RS-2023-00282937
Small molecules								
Small molecules	Type II Diabetes	PAK4					Jeonbuk University Industrial Cooperation Foundation	RS-2021-DD116585
	MASH	Ubiquitin-specific protease-1 (USP1)					Yonsei University	RS-2021-DD115753
	Diabetes	PPAR γ , AMPK					Seoul National University Hospital	RS-2021-DD116739
	Diabetes	Sodium-glucose co-transporter-1 and 2 (SGLT1/2)					Jeil Pharmaceutical Co., Ltd.	RS-2021-DD118514
	Diabetes, Obesity	Atypical Protein Kinase C (aPKC)					Yonsei University	RS-2021-DD120900
	MASH	MLKL					Hanyang University	RS-2021-DD121073
	Cirrhosis	Sphingomyelin Synthase 1 (SMS1)					Seoul National University	RS-2021-DD121074
	Obesity	IP6 kinase					KAIST	RS-2021-DD121226
	Diabetes, Obesity	PPAR γ S273					KRIBB	RS-2022-DD123898
	MASH	Autophagy					LysoTech	RS-2022-DD124088
	Diabetes	Cannabinoid receptor 1 (CB1)					Sungkyunkwan University	RS-2022-DD123988
	Obesity	Adenosine receptor					Seoul National University	RS-2022-DD129040
	Duchenne muscular dystrophy	Dystrophin					RiboTech	RS-2022-DD129103

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Small molecules	Liver fibrosis	LPAR1					AM Sciences Co., Ltd.	RS-2022-DD128916
	MASH	STK25					KRICT	RS-2023-00218351
	MASH	KARS1 (lysyl-tRNA synthetase 1)					Zymedi	RS-2023-00218823
	MASH	5-hydroxytryptamine (5-HT) receptor 2A (HTR2A)					JD Bioscience Inc.	RS-2023-00218035
	Obesity	ALK7					Gachon University Gil Medical Center	RS-2023-00282576
	Liver fibrosis	Dyrk1B					Therasid Bioscience	RS-2023-00283399
	MASH (Metabolic Associated Steatohepatitis)	Serpin Family					Daewoong Pharmaceutical	RS-2024-00463096
	Alcoholic Liver Disease (ALD)	Innate immune sensor 'ZBP1'					UNIST	RS-2025-02222987
	Diabetes & Metabolic diseases	PPAR γ , AMPK					dalimbitech	RS-2025-02172988
	MASH	KARS1					Zymedi	RS-2025-02202980
	Obesity	****					JW Pharmaceutical	RS-2025-25455548



Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Antibody								
BsAb	wet age-related macular degeneration (wAMD)	Tie2 (TEK receptor tyrosine kinase) and VEGF					MabTics Co., Ltd.	RS-2024-00334041
mAb	Degenerative Retinal Disease	PROX1					CELLIAZ Ltd.	RS-2023-00258166
	Macular degeneration	Human Complement C5					ImmunAbs, Inc.	RS-2023-00282906
	wet AMD/DR	Angiopoietin-2 (Ang2) / Tie2					Neortesbio Co.,Ltd.	RS-2023-00282960
	Macular degeneration	Tie2 receptor					PharmAbcine Inc.	RS-2023-00282791
Gene & Nucleic acids								
ASO	Avellino corneal dystrophy	Mutant TGFBI protein					MediciBIO Co., LTD	RS-2023-00282731
GT-Virus vec.	wAMD	VEGF					ElisiGen	RS-2025-02213615
	Leber Congenital Amaurosis	Genetic variants in the CEP290 gene					Seoul National University	RS-2021-DD120776
	Genetic Retinal disease	PDE6B in retina					Asan Medical Center	RS-2022-DD124040
	Macular degeneration	VEGF-A, VEGF-B and PIGF					CdmoGen	RS-2022-DD123974
	Autosomal dominant Retinitis pigmentosa (adRP)	Rhodopsin mutation RNA					Rznomics inc.	RS-2022-DD124114
	Retinitis pigmentosa	EYS c.4957dupA					Sungkyunkwan University Research & Business Foundation	RS-2022-DD128884
	Retinitis Pigmentosa	Photoreceptor in retina					ENCell	RS-2023-00258840
	Retinitis Pigmentosa	IMPDH1; Autosomal dominant retinitis pigmentosa; adRP; gene editing therapy					University of Ulsan	RS-2023-00283544

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
GT-Virus vec.	Leber's congenital amaurosis 10	CEP290 gene (IVS26 mutation)					GenKore	RS-2024-00339507
	Dry-AMD (Age-related Macular Degeneration), Inherited retinal disease	Nkx3 Homeobox 2 (Nkx3-2)					ICM CO.,LTD.	RS-2024-00344469
RNA therapies	Retinitis Pigmentosa	Retinoid-related Orphan Nuclear Receptor Beta (RORβ)					Olix Pharmaceuticals	RS-2023-00217014
Others-Synth.								
Other-S	Macular degeneration	Pathogenic β-catenin					AREZ	RS-2023-00259081
rProtein								
Fusion protein	wAMD, DME, DR	VEGF-A, VEGF-B, PIGF, Ang-2					ALTEOGEN BIOLOGICS	RS-2025-25449916
rProtein	Dry eye disease	Hyaluronan and proteoglycans, Modulation of CD44 signaling through formation of HAPLN1-containing aggregate by linking hyaluronic acid and proteoglycans					HaplScience Inc.	RS-2023-00217306
	dry-AMD (Age-related Macular Degeneration)	Undisclosed signaling pathway					ILIAS Biologics Inc.	RS-2024-00337789
Small molecules								
Small molecules	Age-related macular degeneration	PKD inhibitor					Kyungpook National University Hospital	RS-2021-DD120784
	Diabetic retinopathy	Transglutaminase 2 (TGase 2)					K-MEDI hub	RS-2021-DD121080
	Diabetic retinopathy	TRAP1 (mitochondrial chaperone)					SMARTIN BIO, Inc.	RS-2021-DD120712
	Diabetic retinopathy	Sodium Glucose Cotransporter 2 (SGLT2)					Daewoong Pharmaceutical	RS-2022-DD124312
	Glaucoma, Ocular hypertension	A3AR					Future Medicine Co., Ltd.	RS-2022-DD128799
	Dry Macular degeneration	Autophagy signal pathway					VASTHERA CO., LTD.	RS-2022-00166507
	Retinal vein occlusion	Nitric oxide (NO)					UNIST	RS-2023-00217242
	Dry AMD	RIPK1 (Receptor-interacting serine/threonine protein kinase 1)					Mother's Pharmaceutical Co., Ltd.	RS-2023-00219642

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Small molecules	Leber hereditary optic neuropathy	NADH:quinone oxidoreductase 1 (NQO1)	■	■			Curome Biosciences Co., Ltd	RS-2023-00259507
	wet age-related macular degeneration (wAMD)	Undisclosed	■				Gachon University	RS-2024-00332803
	Age-related Macular Degeneration	The Bromodomain Extraterminal (BRD) protein	■	■	■	■	BENOBIO Co., Ltd.	RS-2024-00338382
	Presbyopia	Lens proteins	■	■	■	■	eFlask co., Ltd.	RS-2025-02223273
	LHON	Mitochondrial chaperone	■				UNIST	RS-2025-25455041
	AMD	PDK4	■	■	■	■	JD Bioscience Inc.	RS-2025-25446266

Respiratory



Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Antibody								
mAb	Pulmonary emphysema	R060	■				Asan Medical Center	RS-2021-DD115930
	Pulmonary fibrosis	N/A	■	■			FNCT Biotech	RS-2022-DD129036
	idiopathic pulmonary fibrosis	Pulmonary Fibrosis Patients	■	■	■		FNCT Biotech	RS-2024-00461975
	IPF	GTC-D1	■				Good T cells, Inc.	RS-2025-25455100
Gene & Nucleic acids								
ASO	Pulmonary fibrosis	Autotaxin	■				Sookmyung Women's University	RS-2025-02213647
mRNA	IPF	****	■	■	■		Samyang Biopharm	RS-2025-25448962
Others-Bio.								
Exosome	Bronchopulmonary Dysplasia (BPD)	Ago2	■	■			Samsung Medical Center	RS-2022-DD124264
rProtein								
Peptide	Idiopathic pulmonary fibrosis	Integrins	■	■			NEXEL	RS-2022-DD123767
Small molecules								
Small molecules	Asthma	Interleukin 33 (IL-33)	■	■			AZCURIS	RS-2021-DD115857
	Idiopathic pulmonary fibrosis	Chitotriosidase (CHIT1)	■	■			INNOVO Therapeutics	RS-2021-DD115938
	Pneumonia	Foxj1	■	■			Chonnam National University R&BD Foundation	RS-2021-DD116780
	COPD	Chemoattractant leukotriene B4 receptor 2 (BLT2)	■	■			Korea University	RS-2021-DD120886
	Idiopathic pulmonary fibrosis	ALK5 (TGF-βR1)	■	■	■		Autotelic Bio Inc.	RS-2022-00165740

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Small molecules	Idiopathic pulmonary fibrosis	Prolyl-tRNA Synthetase					Daewoong Pharmaceutical	RS-2022-00166689
	Idiopathic pulmonary fibrosis	Autotaxin (ATX)					Bridge Biotherapeutics, Inc	RS-2023-00219938
	Idiopathic pulmonary fibrosis	High Mobility Group Box 1 (HMGB1)					SPARK Biopharma	RS-2023-00259223
	Idiopathic pulmonary fibrosis	ARPC2: Actin related protein complex 2					SapiensBio.Inc	RS-2023-00283815
	asthma	Interleukin-33 (IL-33)					AZCURIS	RS-2024-00333140
	IPF	PDE4B					Jeil Pharmaceutical Co., Ltd.	RS-2025-02213196
Auto-immune Diseases & Progressive Fibrosing Interstitial Lung Disease	gp130					Primo Thera CO., Ltd.	RS-2025-25452684	

Cardiovascular



Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Antibody								
mAb	Pulmonary hypertension	Amino-terminal domain of membrane KARS1 (lysyl-tRNA synthetase 1)					Zymedi	RS-2023-00283541
Gene & Nucleic acids								
ASO	Acute heart failure	miRNA					StemMeditech	RS-2021-DD118615
	myocardial infarction	miR 145					Regeninnopharm Inc.	RS-2024-00333652
GT-Virus vec.	Pulmonary hypertension	Pulmonary Arterial Smooth Muscle Cell (PASMC)					GluGene Therapeutics	RS-2023-00217737
Other-GT	Peripheral arterial disease, Diabetic peripheral neuropathy	Hepatocyte growth factor (HGF)					G&P Bioscience	RS-2021-DD118433
rProtein								
Peptide	Pulmonary hypertension	Protein Phosphatase 1 (PP1)					NadianBio	RS-2021-DD121297
Small molecules								
Small molecules	Congestive heart failure, Chronic renal disease	pendrin					Yonsei University	RS-2021-DD116199
	Aortic Stenosis	Dipeptidyl Peptidase-4 (DPP-4)					REDNVIA	RS-2021-DD120950
	Pulmonary hypertension	PDGFR					Voronoj, Inc	RS-2022-00165937
	Aortic stenosis	Tissue Non-specific Alkaline Phosphatase (TNAP)					REDNVIA	RS-2023-00217370
	Pulmonary arterial hypertension	Peroxiredoxin II (PRDX2)					VASTHERA CO., LTD.	RS-2024-00338193
	Anticoagulant	ANO6					S2Cbio Inc.	RS-2025-02213140

Gastrointestinal



Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Others-Synth.								
MRI contrast agent	Magnetic resonance cholangiopancreatography (MRCP)	N/A					Inventera Inc.	RS-2025-25453205
Small molecules								
Small molecules	Dyspepsia	Ghrelin receptor					Kyungpook National University	RS-2021-DD116562
	Cholelithiasis	Gallstone					Surginex	RS-2022-00167125

Others



Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Antibody								
ADC	Osteoporosis	Cathepsin K					Ewha Womans University Industry-Academic Cooperation Foundation	RS-2021-DD116299
BsAb	Organ Failure (incompatible blood type)	Blood group antigen-specific B Cell Receptor (BCR) / CD3 epsilon					KAIST	RS-2021-DD120922
mAb	Hair Loss	CXCL12					EpiBiotech	RS-2022-DD123783
	Acute Kidney Injury	Tie2 (TEK receptor tyrosine kinase)					MabTics Co., Ltd.	RS-2023-00217918
	sudden sensorineural hearing loss	FAM19A5 (functioning synapse elimination)					Neuracle Science Co., Ltd.	RS-2024-00332473
Gene & Nucleic acids								
RNA therapies	Sarcopenia	N/A					AVENTI, Inc.	RS-2021-DD116747
	Androgenetic alopecia	Androgen receptor (AR)					Olix Pharmaceuticals	RS-2023-00259300
Others-Bio.								
Exosome	Lesch-Nyhan syndrome	Deficiency of hypoxanthine-guanine phosphoribosyltransferase activity					MDimune Inc.	RS-2024-00337778
	CKD	Major transcriptional regulator of inflammatory responses					ILIAS Biologics Inc.	RS-2025-02073027
	****	****					ILIAS Biologics Inc.	RS-2025-25444945
Microbiome	Trimethylaminuria	Decomposition of trimethylamine (TMA) by BM 109					BioMe, Inc.	RS-2024-00443597
Other-B	Hearing loss	mitochondria					Paean Biotechnology Inc.	RS-2023-00283926

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Others-Synth.								
MRI contrast agent	MRI contrast agent	Gd-ligand					Hana Pharm	RS-2021-DD121275
	Diagnostic	Organic Anion Transporting Polypeptide (OATP) transporter					PharmGen Science, Inc.	RS-2022-DD123981
	Lymphadenopathy	N/A					Inventera Inc.	RS-2023-00282888
	Diagnostic	Gadolinium Based Liver-specific Contrast Agent					PharmGen Science, Inc.	RS-2024-00462636
rProtein								
Peptide	Sarcopenia	Myoblast					Asan Medical Center	RS-2021-DD120859
	Achondroplasia	Natriuretic peptide receptor B (NPR-B)					Peptron, Inc	RS-2021-DD121201
	Diabetic foot ulcer	let 7 miRNA					StemMeditech	RS-2022-00165887
	Wilson disease	Abnormally accumulated Copper eliminates from the body, especially Liver tissue					ARBORMED Co., Ltd.	RS-2023-00218925
	Wilson's disease	Abnormally accumulated copper in the liver					ARBORMED Co., Ltd.	RS-2025-02213496
rProtein	Sarcopenia	CLCF1 receptor					KRIBB	RS-2022-DD124146
	Others	Hyaluronic acid					Alteogen	RS-2022-DD123890
	Sarcopenia	NOTCH1 receptor					NUON Bio	RS-2022-00165803
	Gout	Uric acid					ProAbTech	RS-2023-00219125
	Degenerative arthritis	Cartilage tissue regeneration					Darnatein	RS-2023-00258278
	Haemophilia A, B	****					TiumBio Co., Ltd.	RS-2023-00282592
	Sarcopenia	NOTCH1					NB Science Co., Ltd.	RS-2025-25453248
	Small molecules							
Small molecules	Hearing loss	Serine/Threonine Kinase 17a (STK17A)					Kyungpook National University	RS-2021-DD115595
	Genetic Hearing Loss	KV7.4					Yonsei University, University-Industry Foundation	RS-2021-DD115781

Drug Class	Indication	Targets	Development Stage				Company	Project ID
			Discovery	Pre	Ph1	Ph2		
Small molecules	Lymphedema	Nrf 2 (Nuclear factor erythroid-2-related factor 2) signaling pathway					RAPPELER	RS-2022-DD123863
	Osteoarthritis	OSCAR					KaiPharm Co., Ltd.	RS-2022-00167006
	Androgenetic alopecia	GFRA1 (GDNF Family Receptor Alpha 1)					JW Pharmaceutical	RS-2023-00217372
	Bladder disease	BKCa channel					GIST	RS-2023-00258812
	Hyperhidrosis	Acetylcholine receptor					eFlask co., Ltd.	RS-2023-00258121
	Progeria syndromes	Progerin protein and Lamin A binding					PRG S&Tech Inc.	RS-2023-00258708
	Osteoarthritis	Inflammasome (inhibition)					INNOVO Therapeutics	RS-2023-00282719
	Sarcopenia	Prokineticin receptor 1 (PROKR1/GPR73)					Seoul National University	RS-2024-00336938
	Alopecia areata	Sphingosine-1-phosphate receptor (S1PR) 1 and 4					NEXTGEN Bioscience	RS-2024-00332313
	Sensorineural hearing loss (noise-induced, ototoxic, and hereditary)	Kv7.4 (K+) channel					iN Therapeutics	RS-2024-00349857
	Sepsis	ASM					K-MEDI hub	RS-2025-02213034
	Sarcopenia	**** receptor					AVENTI, Inc.	RS-2025-02213042
	Sarcopenia	mTORC2					Aliad Biopharma Inc.	RS-2025-02223270
	DKD	NOX inhibitor					Aptabio	RS-2025-02073057
	DMD	CDO					AniMusCure Inc	RS-2025-25451838
CKD	NUAK1					Genome &Company	RS-2025-25453255	
CKD	****					Yuhan / R&D Institute	RS-2025-25451385	
TPD								
PROTAC	Osteoarthritis	****					Seoul National University	RS-2023-00217266

KOREA VERSION 5.0
**DRUG
DEVELOPMENT
FUND**

Published by	Korea Drug Development Fund
Publication date	February 2026
Address	9F KPX Building, 137 Mapodaero, Mapo-gu, Seoul, 04143, Korea
Tel	+82-2-6379-3066
E-mail	kddf_bd@kddf.org
Website	www.kddf.org/en

